#Intratumoral heterogenous population
Can IntraTumoral Heterogeneity Be Thought of as a Mechanism of Resistance?
Curator/Reporter: Stephen J. Williams, Ph.D.
Therapeutic resistance remains one of the most challenging problems for the oncologist, despite the increase of new therapeutics in the oncologist’s toolkit. As new targeted therapies are developed, and new novel targets are investigated as potential therapies, especially cytostatic therapies which it has become evident our understanding of chemoresistance is expanding beyond mechanisms to circumvent a drug’s pharmacologic mechanism of action (i.e. increased DNA repair and cisplatin) or pharmacokinetic changes (i.e. increased efflux by acquisition of a MDR phenotype).
In a talk at the 2015 AACR National Meeting, Dr. Charles Swanton discusses the development of tumor heterogeneity in the light of developing, or acquired, drug resistance. Chemoresistance is either categorized as acquired resistance (where resistance develops upon continued exposure to drug) or inherent resistance (related to a tumor being refractory or unresponsive to drug)…
View original post 7,577 more words
#iblogstats 
Mostly quite beyond my comprehension, but most certainly interesting and importantly educational. Thank you for the link!
LikeLiked by 1 person
Sure1 ( Hands still raw, but cannot resist a discussion on neural networks or tumors). I feel that the current arms of treatments and regimens don’t take the advantages a tumor has.
LikeLiked by 1 person